The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 17 - 2025 |
doi: 10.3389/fnagi.2025.1501762
This article is part of the Research Topic A comprehensive look at biomarkers in neurodegenerative diseases: from early diagnosis to treatment response assessment View all 20 articles
Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease
Provisionally accepted
Yali Xu
1,2*
Jie Zhang
1,2
Ying-Ying Shen
3
Wei-Wei Li
3
Bin Li
1,2
Hai-Ping Cheng
1,2
Gui-Hua Zeng
3- 1 Chongqing General Hospital, Chongqing, China
- 2 Chongqing University, Chongqing, China
- 3 Army Medical University, Chongqing, China
Introduction: The role of the chemokine CX3CL1 in the processes of aging and Alzheimer's disease (AD) pathogenesis is well-established. This study aims to evaluate the diagnostic potential of urinary CX3CL1 levels in distinguishing between AD patients, those experiencing amnestic mild cognitive impairment (aMCI), and cognitively normal (CN) individuals. Methods: A cohort comprising 516 CN individuals across various age groups, 102 AD patients, and 65 subjects with aMCI was assembled, alongside 93 age-and sex-matched CN controls. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify urinary CX3CL1 levels. Results: Urinary CX3CL1 concentrations exhibited an age-dependent increase and demonstrated a positive correlation with age. Comparatively, AD patients exhibited significantly elevated urinary CX3CL1 levels when contrasted with both the CN controls and the aMCI cohort. Conversely, aMCI patients displayed urinary CX3CL1 levels that were notably reduced in comparison to both the AD and CN groups.Conclusions: Urinary CX3CL1 levels correlate with the aging process and may serve as a potential diagnostic biomarker for both amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD).
Keywords: Alzheimer's disease, Ageing, amnestic mild cognitive impairment, biomarker, Cognitively normal subjects, CX3CL1, diagnosis, Urinary
Received: 25 Sep 2024; Accepted: 08 Jan 2025.
Copyright: © 2025 Xu, Zhang, Shen, Li, Li, Cheng and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yali Xu, Chongqing General Hospital, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.